Repository logo
 
Publication

Applicability of EU(7)-PIM criteria in cross-national studies in European countries

2019-07-24Journal article Open access
Simple item page
dc.contributor.authorFialová, Daniela
dc.contributor.authorBrkić, Jovana
dc.contributor.authorLaffon, Blanca
dc.contributor.authorReissigová, Jindra
dc.contributor.authorGrešáková, Silvia
dc.contributor.authorDogan, Soner
dc.contributor.authorDoro, Peter
dc.contributor.authorTasić, Ljiljana
dc.contributor.authorMarinković, Valentina
dc.contributor.authorValdiglesias, Vanessa
dc.contributor.authorCosta, Solange
dc.contributor.authorKostřiba, Jan
dc.date.accessioned2020-05-09T11:22:47Z
dc.date.available2020-05-09T11:22:47Z
dc.date.issued2019-07-24
dc.descriptionFree PMC article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591668/pdf/10.1177_2042098619854014.pdfpt_PT
dc.description.abstractBackground: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.pt_PT
dc.description.sponsorshipThis project received funding from the EU COST Action IS1402 initiative ‘Ageism: a multi-national, interdisciplinary perspective’ (2015–2018), and from the European Union’s Horizon 2020 research and innovation program EUROAGEISM H2020 under the Marie Sklodowska-Curie grant agreement no. 764632 (2017–2021). It was also supported by the project INOMED (reg. no. CZ. 02.1.01/0.0/0.0/18_069/0010046): the pre-application research into innovative medicines and medical technologies, cofunded by the EU, by SVV 260 417 and the scientific program PROGRESS Q42 at the Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationTher Adv Drug Saf. 2019 Jun 24;10:2042098619854014. doi: 10.1177/2042098619854014. eCollection 2019pt_PT
dc.identifier.doi10.1177/2042098619854014pt_PT
dc.identifier.issn2042-0986
dc.identifier.urihttp://hdl.handle.net/10400.18/6627
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSAGE Publicationspt_PT
dc.relationAn international, multi-disciplinary, multi-sectoral training network on ageism
dc.relation.publisherversionhttps://journals.sagepub.com/doi/10.1177/2042098619854014pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectPIMspt_PT
dc.subjectAgedpt_PT
dc.subjectGeriatricspt_PT
dc.subjectPotentially Inappropriate Medicationspt_PT
dc.subjectRegulatory Measurespt_PT
dc.subjectEuropean Unionpt_PT
dc.titleApplicability of EU(7)-PIM criteria in cross-national studies in European countriespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleAn international, multi-disciplinary, multi-sectoral training network on ageism
oaire.awardURIinfo:eu-repo/grantAgreement/EC/H2020/764632/EU
oaire.citation.startPage204209861985401pt_PT
oaire.citation.titleTherapeutic Advances in Drug Safetypt_PT
oaire.citation.volume10pt_PT
oaire.fundingStreamH2020
project.funder.identifierhttp://doi.org/10.13039/501100008530
project.funder.nameEuropean Commission
rcaap.embargofctDe acordo com o editor online da revista.pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isProjectOfPublicationa4ecc311-1652-4a8a-87f4-9b2257f922f7
relation.isProjectOfPublication.latestForDiscoverya4ecc311-1652-4a8a-87f4-9b2257f922f7

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Applicability of EU(7)-PIM.pdf
Size:
1.01 MB
Format:
Adobe Portable Document Format
Download

Collections

DSA - Artigos em revistas internacionais